Ehab L. Atallah

Ehab L. Atallah

Hematology | Oncology
8800 W. Doyne Ave.
Milwaukee, WI 53226

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 115 publications

Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy.

Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy.

Journal: Leukemia & lymphoma
Published: June 12, 2026

Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.

Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.

Journal: Leukemia
Published: May 05, 2026

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in adult acute myeloid leukemia patients: an analysis of ECOG-ACRIN clinical trials.

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in adult acute myeloid leukemia patients: an analysis of ECOG-ACRIN clinical trials.

Journal: Haematologica
Published: May 04, 2026

Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Journal: Leukemia & lymphoma
Published: April 09, 2026

Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.

Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.

Journal: Hematology (Amsterdam, Netherlands)
Published: October 07, 2025

Outcomes of older patients with TP53-mutated myeloid neoplasms.

Outcomes of older patients with TP53-mutated myeloid neoplasms.

Journal: Blood cancer journal
Published: July 01, 2025

Improving quality of life for patients with chronic myeloid leukemia through supportive care, low-dose therapy, switching, and treatment-free remission.

Improving quality of life for patients with chronic myeloid leukemia through supportive care, low-dose therapy, switching, and treatment-free remission.

Journal: Haematologica
Published: June 23, 2025

Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia.

Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia.

Journal: Leukemia research
Published: May 14, 2025

Has the time for treatment-free remission in Philadelphia chromosome-positive acute lymphoblastic leukemia arrived?

Has the time for treatment-free remission in Philadelphia chromosome-positive acute lymphoblastic leukemia arrived?

Journal: Cancer
Published: May 14, 2025

Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Journal: Haematologica
Published: April 20, 2025

Tyrosine kinase inhibitor discontinuation and reinitiation patterns in CML patients in the US: real-world evidence.

Tyrosine kinase inhibitor discontinuation and reinitiation patterns in CML patients in the US: real-world evidence.

Journal: Leukemia & lymphoma
Published: March 25, 2025

An EMT-like signature as a potential driver of myeloid sarcoma.

An EMT-like signature as a potential driver of myeloid sarcoma.

Journal: Blood neoplasia
Published: March 10, 2025
Showing 1-12 of 115

Last Updated: 09/26/2026